Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane® and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC)

✍ Scribed by H. Rosing; W. W. Ten Bokkel Huinink; R. van Gijn; R. F. M. Rombouts; A. Bult; J. H. Beijnen

• Publisher: Springer-Verlag
• Year: 1999
• Tongue: English
• Weight: 795 KB
• Volume: 24
• Category: Article
• ISSN: 0378-7966
• DOI: 10.1007/bf03190013